ArticleCancer research and treatment2016
Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer.
Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.Breast cancer (Tokyo, Japan) · 2024Trial
- Remote Monitoring of Bioelectrical Impedance in Patients With Breast Cancer-Related Lymphedema: 1-Year Pilot Longitudinal Study.JMIR biomedical engineering · 2026Article
- A dynamic nomogram predicting persistent breast cancer-related lymphedema: a retrospective cohort study in China.Breast cancer (Tokyo, Japan) · 2026Article
- Risk Factors for Persistent Lymphedema Following Modified Axillary Lymph Node Dissection in Breast Cancer Patients: A Retrospective Single-Center Study.International journal of breast cancer · 2026Article
- A Single Institution Experience With Immediate Lymphatic Reconstruction: Impact of Insurance Coverage on Risk Reduction.Journal of surgical oncology · 2025Article
- Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea.BMC cancer · 2025Article
- Nomogram for predicting risk of arm lymphedema following axillary lymph node dissection in breast cancer patients.Frontiers in oncology · 2025Article
- Article
- The impact of rehabilitation sport on breast cancer-related lymphoedema and quality of life.Archives of gynecology and obstetrics · 2023Article
- Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.BMC cancer · 2023Article
- The potential of gas plasma technology for targeting breast cancer.Clinical and translational medicine · 2022Review
- Prediction of breast cancer-related lymphedema risk after postoperative radiotherapyFrontiers in oncology · 2022Article
- Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review.Breast care (Basel, Switzerland) · 2021Article
- Who Will Continuously Depend on Compression to Control Persistent or Progressive Breast Cancer-Related Lymphedema Despite 2 Years of Conservative Care?Journal of clinical medicine · 2020Article
- Prevelance of upper extremity lymphedema and risk factors in patients with mastectomy: Single-center, observational, cross-sectional study.Turkish journal of obstetrics and gynecology · 2020Article
- The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related-lymphedema.Cancer reports (Hoboken, N.J.) · 2020Article
- Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.Physical therapy · 2020Observational
- A scoring system for predicting the risk of breast cancer-related lymphedema.International journal of nursing sciences · 2020Article
- Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation.Radiation oncology (London, England) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to identify risk factors for transient lymphedema (TLE) and persistent lymphedema (PLE) following treatment for breast cancer. MATERIALS AND
methodsA total of 1,073 patients who underwent curative breast surgery were analyzed. TLE was defined as one episode of arm swelling that had resolved spontaneously by the next follow-up; arm swelling that persisted over two consecutive examinations was considered PLE.
resultsAt a median follow-up period of 5.1 years, 370 cases of lymphedema were reported, including 120 TLE (11.2%) and 250 PLE (23.3%). Initial grade 1 swelling was observed in 351 patients, of which 120 were limited to TLE (34%), while the other 231 progressed to PLE (66%). All initial swelling observed in TLE patients was classified as grade 1. In multivariate analysis, chemotherapy with taxane and supraclavicular radiation therapy (SCRT) were associated with development of TLE, whereas SCRT, stage III cancer and chemotherapy with taxane were identified as risk factors for PLE (p < 0.05). The estimated incidence of TLE among initial grade 1 patients was calculated using up to three treatment-related risk factors (number of dissected axillary lymph nodes, SCRT, and taxane chemotherapy). The approximate ratios of TLE and PLE based on the number of risk factors were 7:1 (no factor), 1:1 (one factor), 1:2 (two factors), and 1:3 (three factors).
conclusionOne-third of initial swelling events were transient, whereas the other two-thirds of patients experienced PLE. Estimation of TLE and PLE based on known treatment factors could facilitate prediction of this life-long complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.